Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Darkoh, Charles ^a   Comer, Latoya ^b   Zewdie, Getie ^a   Harold, Stephen ^c   Snyder, Ned ^c,d   DuPont, Herbert L ^a,b,c,d,e,f  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c Kelsey Research Foundation   (United States)

^d Kelsey Seybold Clinic   (United States)

^e CHI ST LUKE S HEALTH BAYLOR ST LUKE S MEDICAL CENTER   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CXCL16 CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FECES ANALYSIS; FEMALE; HUMAN; IDIOPATHIC IRRITABLE BOWEL SYNDROME; IRRITABLE COLON; MALE; PATHOGENESIS; POSTINFECTIOUS IRRITABLE BOWEL SYNDROME;

ADULT; CHEMOKINES; CHEMOTAXIS; FECES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED;

EID: 84899738704     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093144     Document Type: Article

References (44)

1. Lovell RM, Ford AC (2012) Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 10: 712-721 e714.
2. Morita N, Toki S, Hirohashi T, Minoda T, Ogawa K, et al. (1995) Incidence and prevalence of inflammatory bowel disease in Japan: nationwide epidemiological survey during the year 1991. J Gastroenterol 30 Suppl 8: 1-4.
3. Loftus EV Jr (2004) Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterol 126: 1504-1517.
4. Engel MA, Neurath MF (2010) New pathophysiological insights and modern treatment of IBD. J Gastroenterol 45: 571-583.
5. Dupont HL (2011) Gastrointestinal infections and the development of irritable bowel syndrome. Curr. Opinion Infect. Dis 24: 503-508.
6. Ji S, Park H, Lee D, Song YK, Choi JP, et al. (2005) Post-infectious irritable bowel syndrome in patients with Shigella infection. J Gastroenterol and Hepatol 20: 381-386. (Pubitemid 40469337)
7. Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, et al. (2006) Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterol 131: 445-450; quiz 660.
8. Haagsma JA, Siersema PD, De Wit NJ, Havelaar AH (2010) Disease burden of post-infectious irritable bowel syndrome in The Netherlands. Epidem and infect 138: 1650-1656.
9. Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL (2004) Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 99: 1774-1778. (Pubitemid 39237507)
10. Thabane M, Simunovic M, Akhtar-Danesh N, Marshall JK (2009) Development and validation of a risk score for post-infectious irritable bowel syndrome. The Am J Gastroenterol 104: 2267-2274.
11. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, et al. (2004) New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol & Therap 20 Suppl 2: 1-9. (Pubitemid 39237523)
12. DuPont HL, Galler G, Garcia-Torres F, DuPont AW, Greisinger A, et al. (2010) Travel and travelers' diarrhea in patients with irritable bowel syndrome. The Am J Trop Med and Hyg 82: 301-305.
13. Dorn SD, Morris CB, Hu Y, Toner BB, Diamant N, et al. (2009) Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar. J Clin Gastroenterol 43: 214-220.
14. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, et al. (2000) Functional bowel disorder and functional abdominal pain. In: Drossman DA CE, Tally NJ, et al. Rome II The Functional Gastrointestinal Disorders Diagnosis, Pathophysiology and Treatment: A Multinational Consensus. 2nd ed. McLean, Va: Degnon Associates. pp. 351-432.
15. Dunlop SP, Jenkins D, Spiller RC (2003) Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 98: 1578-1583. (Pubitemid 36875351)
16. Hosmer DW, Lemeshow S (2000) Applied Logistic Regression. New York: Wiley.
17. Hosmer DW, Lemeshow S (1999) Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: Wiley.
18. Olszak T, An D, Zeissig S, Vera MP, Richter J, et al. (2012) Microbial exposure during early life has persistent effects on natural killer T cell function. Science 336: 489-493.
19. Day C, Patel R, Guillen C, Wardlaw AJ (2009) The chemokine CXCL16 is highly and constitutively expressed by human bronchial epithelial cells. Exp Lung Res 35: 272-283.
20. Diegelmann J, Seiderer J, Niess JH, Haller D, Goke B, et al. (2010) Expression and regulation of the chemokine CXCL16 in Crohn's disease and models of intestinal inflammation. Inflamm Bowel Dis 16: 1871-1881.
21. Faresjo A, Grodzinsky E, Hallert C, Timpka T (2013) Patients with irritable bowel syndrome are more burdened by co-morbidity and worry about serious diseases than healthy controls- eight years follow-up of IBS patients in primary care. BMC Public Health 13: 832.
22. Hasegawa M, Sato S, Takehara K (1999) Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 117: 159-165. (Pubitemid 29292792)
23. Yoshimura T, Yuhki N, Moore SK, Appella E, Lerman MI, et al. (1989) Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett 244: 487-493. (Pubitemid 19067175)
24. Leonard EJ, Yoshimura T (1990) Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 11: 97-101. (Pubitemid 20062717)
25. Fahey TJ 3rd, Tracey KJ, Tekamp-Olson P, Cousens LS, Jones WG, et al. (1992) Macrophage inflammatory protein 1 modulates macrophage function. J Immunol 148: 2764-2769.
26. Brieland JK, Jones ML, Clarke SJ, Baker JB, Warren JS, et al. (1992) Effect of acute inflammatory lung injury on the expression of monocyte chemoattractant protein-1 (MCP-1) in rat pulmonary alveolar macrophages. Am J Respir Cell Mol Biol 7: 134-139.
27. Jones ML, Mulligan MS, Flory CM, Ward PA, Warren JS (1992) Potential role of monocyte chemoattractant protein 1/JE in monocyte/macrophage-dependent IgA immune complex alveolitis in the rat. J Immunol 149: 2147-2154.
28. Gunn MD, Nelken NA, Liao X, Williams LT (1997) Monocyte chemoattractant protein-1 is sufficient for the chemotaxis of monocytes and lymphocytes in transgenic mice but requires an additional stimulus for inflammatory activation. J Immunol 158: 376-383. (Pubitemid 127483879)
29. Jiang Y, Beller DI, Frendl G, Graves DT (1992) Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 148: 2423-2428.
30. Stahl RA, Thaiss F, Disser M, Helmchen U, Hora K, et al. (1993) Increased expression of monocyte chemoattractant protein-1 in anti-thymocyte antibody-induced glomerulonephritis. Kidney Int 44: 1036-1047. (Pubitemid 23316472)
31. Chang L, Adeyemo M, Karagiannides I, Videlock EJ, Bowe C, et al. (2012) Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 107: 262-272.
32. Chen J, Zhang Y, Deng Z (2012) Imbalanced shift of cytokine expression between T helper 1 and T helper 2 (Th1/Th2) in intestinal mucosa of patients with post-infectious irritable bowel syndrome. BMC Gastroenterol 12: 91.
33. Gao J (2013) Correlation between anxiety-depression status and cytokines in diarrhea-predominant irritable bowel syndrome. Exp Ther Med 6: 93-96.
34. McKernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG (2011) Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther 33: 1045-1052.
35. Rana SV, Sharma S, Sinha SK, Parsad KK, Malik A, et al. (2012) Proinflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients. Trop Gastroenterol 33: 251-256.
36. Romero-Valdovinos M, Gudino-Ramirez A, Reyes-Gordillo J, Martinez-Flores WA, Ramirez-Miranda ME, et al. (2012) Interleukin-8 and -10 gene polymorphisms in irritable bowel syndrome. Mol Biol Rep 39: 8837-8843.
37. Schmulson M, Pulido-London D, Rodriguez O, Morales-Rochlin N, Martinez-Garcia R, et al. (2012) Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico. Am J Gastroenterol 107: 747-753.
38. Swan C, Duroudier NP, Campbell E, Zaitoun A, Hastings M, et al. (2013) Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFalpha. Gut 62: 985-994.
39. Matloubian M, David A, Engel S, Ryan JE, Cyster JG (2000) A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nature Immunol 1: 298-304.
40. Wilbanks A, Zondlo SC, Murphy K, Mak S, Soler D, et al. (2001) Expression cloning of the STRL33/BONZO/TYMSTRligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol 166: 5145-5154. (Pubitemid 32280729)
41. Shimaoka T, Kume N, Minami M, Hayashida K, Kataoka H, et al. (2000) Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem 275: 40663-40666. (Pubitemid 32054881)
42. Ruth JH, Haas CS, Park CC, Amin MA, Martinez RJ, et al. (2006) CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis and rheumatism 54: 765-778.
43. Nanki T, Shimaoka T, Hayashida K, Taniguchi K, Yonehara S, et al. (2005) Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis and rheumatism 52: 3004-3014. (Pubitemid 41447079)
44. Vinolo MA, Rodrigues HG, Nachbar RT, Curi R (2011) Regulation of inflammation by short chain fatty acids. Nutrients 3: 858-876.